Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 1, 2011, Pages 48-53

  Lin, Yen Hung ^a   Huang, Kuo How ^a   Lee, Jen Kuang ^a   Wang, Shuo Meng ^a   Yen, Ruoh Fang ^a   Wu, Vin Cent ^a   Chung, Shiu Dong ^b   Liu, Kao Lang ^a   Chueh, Shih Chieh ^a,c   Lin, Lian Yu ^a   Ho, Yi Lwun ^a   Chen, Ming Fong ^a   Wu, Kwan Dun ^a   Chang, Hung Wei ^d   Hu, Fu Chang ^d   Chen, Yung Ming ^d   Kuo, Chin Chi ^d   Lu, Ching Chu ^d   Chang, Fang Chi ^d   Liao, Shih Cheng ^d   Lin, Wei Chou ^d   Hsieh, Bor Sen ^d   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NONE

Author keywords

adrenalectomy; aldosterone; left ventricular hypertrophy; left ventricular mass index; Primary aldosteronism

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; POTASSIUM; RENIN;

ADRENALECTOMY; ADULT; ALDOSTERONE RELEASE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); CORRELATION COEFFICIENT; DATA BASE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LEFT VENTRICULAR MASS REGRESSION; MALE; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIMARY HYPERALDOSTERONISM; RETROSPECTIVE STUDY;

ADRENALECTOMY; FEMALE; HEART VENTRICLES; HUMANS; HYPERALDOSTERONISM; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED;

EID: 79952560466     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320310376424     Document Type: Article

References (45)

1. Unger T. The role of the rennin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002;89:3A-9A; discussion 10A.
2. Delcayre C, Silvestre JS, Garnier A, et al. Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000;57:1346-51. (Pubitemid 30207889)
3. Weber KT, Brilla CG, Janicki JS, Reddy HK, Campbell SE. Myocardial fibrosis: role of ventricular systolic pressure, arterial hypertension, and circulating hormones. Basic Res Cardiol 1991; 86 Suppl 3:25-31.
4. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
5. Young WF, Jr. Minireview: primary aldosteronism- changing concepts in diagnosis and treatment. Endocrinology 2003;144:2208-13.
6. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002;40:897-902. (Pubitemid 35434913)
7. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994;21:315-8. (Pubitemid 24201225)
8. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997;95:1471-8. (Pubitemid 27142805)
9. Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996;27:1039-45. (Pubitemid 26140658)
10. Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006;19:13-18. (Pubitemid 43217027)
11. Tanabe A, Naruse M, Naruse K, et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res 1997;20:85-90.
12. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-300. (Pubitemid 44873058)
13. Nomura K, Toraya S, Horiba N, Ujihara M, Aiba M, Demura H. Plasma aldosterone response to upright posture and angiotensin II infusion in aldosterone-producing adenoma. J Clin Endocrinol Metab 1992;75:323-7.
14. Goldkorn R, Yurenev A, Blumenfeld J, Fishman D, Devereux RB. Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension. Am J Hypertens 2002;15:340-5. (Pubitemid 34408974)
15. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999;48:756-60. (Pubitemid 29520601)
16. Lumachi F, Ermani M, Basso SM, Armanini D, Iacobone M, Favia G. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg 2005;71:864-9.
17. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001;135:258-61. (Pubitemid 32799339)
18. Proye CA, Mulliez EA, Carnaille BM, et al. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 1998;124:1128-33. (Pubitemid 28555205)
19. Horita Y, Inenaga T, Nakahama H, et al. Cause of residual hypertension after adrenalectomy in patients with primary aldosteronism. Am J Kidney Dis 2001;37:884-9. (Pubitemid 32471846)
20. Wu VC, Chang HW, Liu KL, et al. Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests. Am J Hypertens 2009;22:821-7.
21. Wu VC, Chueh SC, Chang HW, et al. Bilateral aldosterone-producing adenomas: differentiation from bilateral adrenal hyperplasia. QJM 2008;101:13-22.
22. Kuo CC, Yang WS, Wu VC, Tsai CW, Wang WJ, Wu KD. Hypokalemic paralysis: the interplay between primary aldosteronism and hyperthyroidism. Eur J Clin Invest 2009;39:738-9.
23. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008;371:1921-6. (Pubitemid 351778191)
24. Liao CH, Chueh SC, Lai MK, Hsiao PJ, Chen J. Laparoscopic adrenalectomy for potentially malignant adrenal tumors greater than 5 centimeters. J Clin Endocrinol Metab 2006;91:3080-3. (Pubitemid 44271759)
25. Obara T, Ito Y, Okamoto T, et al. Risk factors associated with postoperative persistent hypertension in patients with primary aldosteronism. Surgery 1992;112:987-93. (Pubitemid 23008223)
26. Novitsky YW, Kercher KW, Rosen MJ, Cobb WS, Jyothinagaram S, Heniford BT. Clinical outcomes of laparoscopic adrenalectomy for lateralizing nodular hyperplasia. Surgery 2005;138:1009-16; discussion 16-17.
27. Omura M, Sasano H, Fujiwara T, Yamaguchi K, Nishikawa T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 2002;51:350-5. (Pubitemid 34232637)
28. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-8. (Pubitemid 8066109)
29. Ayus JC, Go AS, Valderrabano F, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int 2005;68:788-95. (Pubitemid 43323135)
30. Rundback JH, Sacks D, Kent KC, et al. Guidelines for the reporting of renal artery revascularization in clinical trials. Circulation 2002;106:1572-85.
31. Catena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50:911-8. (Pubitemid 350287534)
32. Watson T, Karthikeyan VJ, Lip GY, Beevers G. Atrial fibrillation in primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2009;10:190-4.
33. Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005;16:1320-5. (Pubitemid 41716516)
34. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7. (Pubitemid 30094728)
35. Rossi GP, Di Bello V, Ganzaroli C, et al. Excess aldoste- aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002;40:23-7. (Pubitemid 34755974)
36. Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography. Part II. Clinical studies. Mayo Clin Proc 1989;64:181-204. (Pubitemid 19080935)
37. Pearson AC, Labovitz AJ, Mrosek D, Williams GA, Kennedy HL. Assessment of diastolic function in normal and hypertrophied hearts: comparison of Doppler echocardiography and M-mode echocardiography. Am Heart J 1987;113:1417-25.
38. De Boeck BW, Cramer MJ, Oh JK, van der Aa RP, Jaarsma W. Spectral pulsed tissue Doppler imaging in diastole: a tool to increase our insight in and assessment of diastolic relaxation of the left ventricle. Am Heart J 2003;146:411-9. (Pubitemid 37083075)
39. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990;81:528-36. (Pubitemid 20055961)
40. Verdecchia P, Schillaci G, Borgioni C, Gattobigio R, Ambrosio G, Porcellati C. Prevalent influence of systolic over pulse pressure on left ventricular mass in essential hypertension. Eur Heart J 2002;23:658-65. (Pubitemid 35204251)
41. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
42. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6. (Pubitemid 20176696)
43. Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16:895-9. (Pubitemid 37315486)
44. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9. (Pubitemid 39491918)
45. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8. (Pubitemid 40523144)